ArticleJournal of translational medicine2025
A multi-omics Mendelian randomization study reveals PAM as a potential therapeutic target for type 2 diabetes.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Screen Time and Chronic Pain Health: Mendelian Randomization Study.Journal of medical Internet research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe progression of type 2 diabetes (T2D) is driven by pancreatic β-cell dysfunction and loss, yet current therapies fail to address this core pathophysiology.
methodsWe implemented an integrative pipeline combining genetic and functional data to prioritize T2D targets. We leveraged genome-wide association study (GWAS) and protein quantitative trait loci (pQTL) summary data to infer causal associations between circulating proteins and disease risk. Phenome-wide association studies were conducted to evaluate pleiotropy and potential off-target effects. Single-cell RNA-seq was used to delineate cell-type-specific expression and identify biological pathways associated with candidate genes. Lead candidates were then validated by molecular docking and functional assays.
findingsMendelian randomization and colocalization analyses prioritized 14 circulating proteins with causal links to T2D, nine of which shared strong causal variants (PPH4 > 0.8). Phenome-wide association studies (PheWAS) excluded off-target effects for 2 candidates (HP and SVEP1). Among the remaining 7 candidates (ENG, GOLM1, GSTA1, HIBCH, PAM, PLXND1, and PTN), PAM (peptidylglycine α-amidating monooxygenase) was found to be expressed in over 80% of β-cells, as revealed by single-cell RNA-sequencing. Moreover, genes co-expressed with PAM were functionally clustered in pathways related to insulin secretion and protein processing. Notably, PAM expression was significantly downregulated in islets of diabetic mice. Molecular docking simulations identified a high-affinity interaction between PAM and oleic acid (OA), a metabolite linked to β-cell function. Strikingly, pharmacological PAM inhibition in INS1 β-cells induced deficits in cell proliferation and survival that were unresponsive to OA supplementation, underscoring PAM's indispensable role in β-cell integrity.
interpretationThis study positions PAM as a clinically relevant therapeutic target for T2D, offering new opportunities for β-cell preservation therapies and diagnostic biomarker development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.